Clinical Guidelines from ACP

Featured Clinical Guideline

ACP's Best Practice Advice for Cervical Cancer Screening

Full text

Recent Guidelines Topics from ACP

Risk Assessment and Prevention of Pressure Ulcers

Full text
View ACP Guidelines on your smartphone. Mobile

ACP develops three different types of clinical recommendations:

Clinical Practice Guidelines, Clinical Guidance Statements, and Best Practice Advice. ACP's goal is to provide clinicians with recommendations based on the best available evidence; to inform clinicians of when there is no evidence; and finally, to help clinicians deliver the best health care possible.

Access all Guidelines

Our goal is to help clinicians deliver the best health care possible.

The American College of Physicians (ACP) established its evidence-based clinical practice guidelines program in 1981. The ACP clinical practice guidelines and guidance statements follow a multistep development process that includes a systematic review of the evidence, deliberation of the evidence by the committee, summary recommendations, and evidence and recommendation grading.

Of Interest and Note...

Online High Value Cases
  • Online High Value Cases: A series of High Value Care case studies are available for free to help clinicians understand the benefits, harms, and costs of tests and treatment options for common clinical issues so they can pursue care that improves health and eliminates wasteful practices.
  • ACP's Mobile Resources include a variety of applications, mobile web resources, and mobile documents to support your clinical practice.

A 58-year-old woman is evaluated during a routine physical examination. She has a history of atrial fibrillation and had an atrial fibrillation ablation procedure 6 months ago. Before her ablation, she had persistent atrial fibrillation with palpitations and dyspnea. Since her ablation, she has been asymptomatic with no palpitations. Ambulatory electrocardiographic monitoring at 3 and 6 months after the ablation demonstrated no atrial fibrillation. Medical history is also significant for a transient ischemic attack, hypertension, and hyperlipidemia. Her medications are warfarin, metoprolol, candesartan, and simvastatin.

On physical examination, the patient is afebrile, blood pressure is 130/80 mm Hg, pulse rate is 64/min, and respiration rate is 16/min. BMI is 30. Heart rate and rhythm are regular.

An electrocardiogram shows normal sinus rhythm.


Which of the following is the most appropriate management?

This patient should continue taking warfarin. She has a history of symptomatic atrial fibrillation and is now symptom-free without evidence of recurrent atrial fibrillation after catheter ablation. However, patients with successful ablation and elimination of symptoms may have transient asymptomatic atrial fibrillation with continued risk for atrial fibrillation-associated thromboembolic disease. Therefore, current consensus recommendations counsel that stroke prevention therapy following atrial fibrillation ablation be based on risk factors and not rhythm status, with the preferred risk stratification tool being the CHA2DS2-VASc risk score, which has improved predictive ability relative to the CHADS2 score. The patient is a 58-year-old woman with a prior transient ischemic attack (TIA) and hypertension. Accordingly, her CHA2DS2-VASc risk score is 4 (2 points for TIA, 1 point for hypertension, and 1 point for female sex). Current guidelines advocate oral anticoagulation for any patient with nonvalvular atrial fibrillation and a CHA2DS2-VASc score greater than 1. She has a history of a central nervous system event, and her annual risk of stroke is high (greater than 5% annually). Therefore, she should be continued on anticoagulation with warfarin.

Concomitant aspirin therapy with warfarin is reserved for patients with active coronary artery disease. This patient has risk factors for atherosclerosis, but she does not have a history of coronary artery disease or acute coronary syndromes. The addition of aspirin to warfarin significantly increases the risk of bleeding.

Discontinuation of warfarin and substitution with aspirin or dual antiplatelet therapy is not correct. Aspirin is insufficient therapy for a patient at high risk of stroke. The Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE-W) trial compared warfarin with therapy with aspirin and clopidogrel and found that aspirin with clopidogrel was inferior to warfarin for stroke prevention with no statistically significant difference in bleeding.

Anticoagulation with a novel oral anticoagulant (such as dabigatran, rivaroxaban, or apixaban) could be considered; however, these agents have been associated with increased gastrointestinal bleeding compared with warfarin.

Key Point

  • Stroke prevention therapy after catheter ablation of atrial fibrillation should be based upon risk stratification, not heart rhythm status.
Selected ACP Member Benefits
ACP JournalWise
ACP JournalWise

Online and optimized for mobile use, ACP JournalWise alerts you to the highest quality, most clinically relevant new articles in your preferred areas of specialty and with a frequency that you select.

Begin Search | Learn More

DynaMed Plus
DynaMed PlusTM

The next-generation clinical information resource delivers the most current, evidence-based recommendations at the point-of-care.

Sign In | Learn More

In the Clinic
In the Clinic

Evidence-based answers to frequently asked questions about screening, prevention, diagnosis, and therapy for common clinical conditions. Plus, downloadable slide sets to improve quality of care are available free to members.

In the Clinic | Access Slide Sets
Clinical Multimedia